SG Americas Securities LLC Buys New Stake in 2seventy bio, Inc. (NASDAQ:TSVT)

SG Americas Securities LLC acquired a new stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 16,890 shares of the company’s stock, valued at approximately $80,000.

Several other institutional investors and hedge funds have also modified their holdings of TSVT. Stonepine Capital Management LLC acquired a new stake in 2seventy bio during the second quarter worth about $385,000. SkyView Investment Advisors LLC increased its holdings in shares of 2seventy bio by 25.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock valued at $48,000 after purchasing an additional 2,500 shares in the last quarter. Susquehanna Fundamental Investments LLC lifted its stake in shares of 2seventy bio by 39.1% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock valued at $740,000 after purchasing an additional 54,076 shares during the period. Marshall Wace LLP boosted its holdings in 2seventy bio by 50.4% during the second quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock worth $2,568,000 after buying an additional 223,408 shares in the last quarter. Finally, Venator Management LLC boosted its holdings in 2seventy bio by 49.2% during the second quarter. Venator Management LLC now owns 485,000 shares of the company’s stock worth $1,867,000 after buying an additional 160,000 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Ratings Changes

Separately, Morgan Stanley decreased their price objective on shares of 2seventy bio from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. One analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, 2seventy bio currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

2seventy bio Stock Up 2.7 %

Shares of NASDAQ TSVT opened at $4.98 on Tuesday. The firm has a market cap of $256.47 million, a price-to-earnings ratio of -1.62 and a beta of 1.77. The company’s 50-day simple moving average is $4.76 and its 200-day simple moving average is $4.51. 2seventy bio, Inc. has a 52-week low of $1.53 and a 52-week high of $6.40.

2seventy bio (NASDAQ:TSVT) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.06. 2seventy bio had a negative return on equity of 66.01% and a negative net margin of 354.16%. The company had revenue of $8.97 million for the quarter, compared to analysts’ expectations of $11.43 million. Equities research analysts anticipate that 2seventy bio, Inc. will post -1.23 EPS for the current fiscal year.

Insider Transactions at 2seventy bio

In related news, insider Jessica Snow sold 7,816 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $4.32, for a total value of $33,765.12. Following the completion of the transaction, the insider now directly owns 156,330 shares of the company’s stock, valued at approximately $675,345.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.20% of the company’s stock.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.